Author archive
By MICHAEL MILLENSON Twenty years ago this month, the Boston Globe disclosed that health columnist Betsy Lehman, a 39-year-old mother of two, had been killed by a drug overdose during treatment for breast cancer at Dana-Farber Cancer Center. In laying out a grim trail of preventable mistakes at a renowned institution, the Globe prompted local […]
Dr. Charles Denham, a physician-turned-entrepreneur-and-activist, has agreed to pay $1 million to settle government charges of taking a $12 million kickback to influence a national patient safety standard in favor of one company’s product. Though the l…
Dr. Charles Denham, a physician-turned-entrepreneur-and-activist, has agreed to pay $1 million to settle government charges of taking a $12 million kickback to influence a national patient safety standard in favor of one company’s product. Though the l…
By MICHAEL MILLENSON A few years ago, I was upgraded to First Class on a flight from California back to Chicago. Not long after I settled in, a tall, muscular man easily four inches taller than me walked up to my aisle seat in the first row and prepared to sit by the window. I envisioned […]
The deal to produce clinical summaries under the Mayo Clinic name for Google searches symbolizes the medical priesthood’s acceptance that information technology has reshaped the doctor-patient relationship. More disruptions are already on the way.
The deal to produce clinical summaries under the Mayo Clinic name for Google searches symbolizes the medical priesthood’s acceptance that information technology has reshaped the doctor-patient relationship. More disruptions are already on the way.
After 15 years of asking consumers around the world about who they trust and why, Edelman CEO Richard Edelman offers advice on boosting trust and why it helps earnings and innovation.
After 15 years of asking consumers around the world about who they trust and why, Edelman CEO Richard Edelman offers advice on boosting trust and why it helps earnings and innovation.
The biotech industry cheered President Obama’s proposed $215 million Precision Medicine Initiative, but the varying results and genetic basis of three DNA-based tests to predict breast cancer recurrence show the gap remaining between branding and real …
The biotech industry cheered President Obama’s proposed $215 million Precision Medicine Initiative, but the varying results and genetic basis of three DNA-based tests to predict breast cancer recurrence show the gap remaining between branding and real …